Oncolytic virus, DNA-tumor virus; Persistent infection, Hematopoietic stem cell transduction, Phenotypic variability of infection, Light microscopy, Anti-virals
Viruses have been associated with cancer in two ways –as cancer-causing viruses, and cancer-disruptingvectors. Regardless oftheir effects, all viruses have a dual nature. Particles are ‘passive substances’ lacking chemical energy transformation processes, whereas infected cells are ‘active substances’ turning-over energy, and causing disease. How virions (passive substances) convert to infected cells (active substances) has been a long-standing question in my laboratory.
How do viruses work,and how can virus vectors be best used in anti-cancer treatments? To address virus-cancer interactions, our research focusses on human adenoviruses, which infect a wide range of cell types. Infection outcome dependson innate and adaptive anti-viral immunity,and the viral use of host cell mechanisms. We engage forward genetics, system-wide analyses of proteins, lipids and nucleic acids, as well asstudies of molecules, organelles, cells and micro-tissue. Advanced light and electron microscopy, biochemical and cell biological tests, systems profiling and numerical models further enhance our analyse sof viral infection.We additionally have a strong interest in identifying chemical compounds with anti-viral activity, and elucidating their mode-of-action to stop natural infections, and safeguard against uncontrolled outbreak of replicating anti-cancer vectors. Further efforts of my laboratory explorehow viruses adapt to a dynamic host environment and to therapeutic pressure, which can occur in cancer therapy, for example. Our studies contribute to a better understanding of how viruses break down the defense barriers of the host. They provide a strong basis for clinical gene therapy, a field, which largely relies on viral vectors.Publications